Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IDXX IDEXX Laboratories	$542.65 +1.2%	$504.03	$356.14 ▼ $546.39	$43.13B	1.54	645,848 shs	631,445 shs
IQV IQVIA	$162.54 +3.1%	$149.96	$134.65 ▼ $252.88	$27.26B	1.3	1.64 million shs	1.50 million shs
MCO Moody's	$502.24 +0.1%	$474.70	$378.71 ▼ $531.93	$90.24B	1.38	760,566 shs	813,546 shs
NVST Envista	$20.00 +2.3%	$17.99	$14.22 ▼ $23.00	$3.31B	1	2.49 million shs	2.68 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IDXX IDEXX Laboratories	+1.18%	+2.29%	+5.88%	+27.31%	+13.91%
IQV IQVIA	+3.08%	+2.46%	+15.97%	-6.86%	-22.04%
MCO Moody's	+0.02%	+2.63%	+4.81%	+6.48%	+19.16%
NVST Envista	+2.12%	+5.71%	+9.32%	+14.32%	+24.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IDXX IDEXX Laboratories	3.7122 of 5 stars	1.4	4.0	0.0	3.7	3.0	2.5	1.3
IQV IQVIA	4.8851 of 5 stars	4.4	2.0	0.0	4.6	2.6	1.7	2.5
MCO Moody's	4.3294 of 5 stars	2.3	3.0	3.3	3.2	2.2	2.5	1.3
NVST Envista	3.452 of 5 stars	2.2	3.0	0.0	3.8	1.4	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IDXX IDEXX Laboratories	2.80	Moderate Buy	$554.78	2.23% Upside
IQV IQVIA	2.75	Moderate Buy	$226.32	39.24% Upside
MCO Moody's	2.53	Moderate Buy	$519.40	3.42% Upside
NVST Envista	2.33	Hold	$20.23	1.18% Upside

Current Analyst Ratings Breakdown

Latest IDXX, IQV, MCO, and NVST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	IDXX IDEXX Laboratories	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$625.00
6/11/2025	IDXX IDEXX Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$515.00 ➝ $580.00
6/5/2025	MCO Moody's	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$489.00 ➝ $523.00
6/4/2025	MCO Moody's	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$550.00
5/27/2025	MCO Moody's	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$550.00
5/27/2025	NVST Envista	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/27/2025	NVST Envista	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$21.00 ➝ $23.00
5/23/2025	IQV IQVIA	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$188.00
5/22/2025	IQV IQVIA	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/19/2025	IDXX IDEXX Laboratories	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$460.00 ➝ $510.00
5/19/2025	IQV IQVIA	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$232.00 ➝ $177.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IDXX IDEXX Laboratories	$3.90B	11.20	$12.58 per share	43.15	$19.48 per share	27.86
IQV IQVIA	$15.41B	1.83	$17.13 per share	9.49	$33.43 per share	4.86
MCO Moody's	$7.09B	12.75	$14.97 per share	33.54	$20.57 per share	24.42
NVST Envista	$2.51B	1.35	$1.70 per share	11.76	$17.05 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IDXX IDEXX Laboratories	$887.87M	$10.82	50.15	39.96	3.92	22.76%	57.35%	26.97%	8/4/2025 (Confirmed)
IQV IQVIA	$1.37B	$7.34	22.14	13.32	1.75	8.61%	29.16%	6.96%	7/28/2025 (Estimated)
MCO Moody's	$2.06B	$11.58	43.37	32.19	2.88	29.15%	60.37%	15.33%	7/22/2025 (Estimated)
NVST Envista	-$1.12B	-$6.53	N/A	16.52	1.24	-44.90%	4.07%	2.25%	8/6/2025 (Estimated)

Latest IDXX, IQV, MCO, and NVST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/28/2025	Q2 2025	IQV IQVIA	$2.76	N/A	N/A	N/A	N/A	N/A
7/22/2025	Q2 2025	MCO Moody's	$3.30	N/A	N/A	N/A	$1.82 billion	N/A
5/6/2025	Q1 2025	IQV IQVIA	$2.63	$2.70	+$0.07	$1.40	$3.77 billion	$3.83 billion
5/1/2025	Q1 2025	IDXX IDEXX Laboratories	$2.93	$2.96	+$0.03	$2.96	$998.25 million	$998.43 million
5/1/2025	Q1 2025	NVST Envista	$0.20	$0.24	+$0.04	$0.10	$608.17 million	$616.90 million
4/22/2025	Q1 2025	MCO Moody's	$3.58	$3.83	+$0.25	$3.46	$1.90 billion	$1.92 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A
IQV IQVIA	N/A	N/A	N/A	N/A	N/A
MCO Moody's	$3.76	0.75%	N/A	32.47%	16 Years
NVST Envista	N/A	N/A	N/A	N/A	N/A

Latest IDXX, IQV, MCO, and NVST Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	MCO Moody's	quarterly	$0.94	0.9%	5/16/2025	5/16/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IDXX IDEXX Laboratories	0.31	1.16	0.81
IQV IQVIA	2.19	0.82	0.82
MCO Moody's	1.77	1.57	1.56
NVST Envista	0.43	2.12	1.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IDXX IDEXX Laboratories	87.84%
IQV IQVIA	89.62%
MCO Moody's	92.11%
NVST Envista	N/A

Insider Ownership

Company	Insider Ownership
IDXX IDEXX Laboratories	0.98%
IQV IQVIA	1.60%
MCO Moody's	0.14%
NVST Envista	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IDXX IDEXX Laboratories	11,000	80.42 million	79.63 million	Optionable
IQV IQVIA	88,000	173.00 million	170.23 million	Optionable
MCO Moody's	15,838	179.90 million	179.65 million	Optionable
NVST Envista	12,300	169.49 million	167.28 million	Optionable

IDXX, IQV, MCO, and NVST Headlines

Recent News About These Companies

Envista (NVST) and The Competition Head to Head Analysis

4 hours ago | americanbankingnews.com

Marathon Asset Management Ltd Has $16.63 Million Stock Position in Envista Holdings Corporation (NYSE:NVST)

June 28, 2025 | marketbeat.com

5 Must-Read Analyst Questions From Envista’s Q1 Earnings Call

June 27, 2025 | msn.com

NVST vs. ABT: Which Stock Is the Better Value Option?

June 26, 2025 | zacks.com

Why Envista Holdings Corporation (NYSE:NVST) Could Be Worth Watching

June 25, 2025 | finance.yahoo.com

Envista Holdings Shows Rising Relative Strength; Still Shy Of Key Benchmark

June 23, 2025 | msn.com

Envista Holdings Corporation (NYSE:NVST) Receives Consensus Recommendation of "Hold" from Analysts

June 23, 2025 | marketbeat.com

Should You Add NVST Stock to Your Portfolio Right Now?

June 19, 2025 | zacks.com

GAMMA Investing LLC Raises Stock Holdings in Envista Holdings Corporation (NYSE:NVST)

June 19, 2025 | marketbeat.com

Envista Holdings Co. (NYSE:NVST) Shares Acquired by SG Americas Securities LLC

June 16, 2025 | marketbeat.com

1 Cash-Producing Stock with Exciting Potential and 2 to Turn Down

June 12, 2025 | msn.com

Envista Holdings Co. (NYSE:NVST) Shares Sold by Wedge Capital Management L L P NC

June 12, 2025 | marketbeat.com

All You Need to Know About Envista (NVST) Rating Upgrade to Buy

June 10, 2025 | zacks.com

NVST vs. ABT: Which Stock Should Value Investors Buy Now?

June 10, 2025 | zacks.com

3 Reasons to Sell NVST and 1 Stock to Buy Instead

June 9, 2025 | msn.com

Envista Holdings Co. (NYSE:NVST) Sees Significant Drop in Short Interest

June 3, 2025 | marketbeat.com

Envista Holdings Co. (NYSE:NVST) Shares Sold by Squarepoint Ops LLC

June 3, 2025 | marketbeat.com

Two Sigma Advisers LP Increases Stock Holdings in Envista Holdings Co. (NYSE:NVST)

June 2, 2025 | marketbeat.com

Envista Holdings Co. (NYSE:NVST) Stock Holdings Lessened by Millennium Management LLC

June 2, 2025 | marketbeat.com

Baird Upgrades Envista Holdings (NVST) Stock to Outperform, Raises PT

May 29, 2025 | msn.com

Baird Upgrades Envista Holdings (NVST)

May 28, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDXX, IQV, MCO, and NVST Company Descriptions

IDEXX Laboratories NASDAQ:IDXX

$542.65 +6.31 (+1.18%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$542.90 +0.25 (+0.05%)

As of 07/1/2025 07:44 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IQVIA NYSE:IQV

$162.54 +4.95 (+3.14%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$162.49 -0.05 (-0.03%)

As of 05:36 AM Eastern

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Moody's NYSE:MCO

$502.24 +0.65 (+0.13%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$492.28 -9.97 (-1.98%)

As of 05:06 AM Eastern

Moody's Corporation operates as an integrated risk assessment firm worldwide. It operates in two segments, Moody's Analytics and Moody's Investors Services. The Moody's Analytics segment develops a range of products and services that support the risk management activities of institutional participants in financial markets. It also offers credit research, credit models and analytics, economics data and models, and structured finance solutions; data sets on companies and securities; and SaaS solutions supporting banking, insurance, and know your customer workflows. The Moody's Investors Service segment publishes credit ratings and provides assessment services on various debt obligations, programs and facilities, and entities that issue such obligations, such as various corporate, financial institution, and governmental obligations, as well as structured finance securities. The company was formerly known as Dun and Bradstreet Company and changed its name to Moody's Corporation in September 2000. Moody's Corporation was founded in 1900 and is headquartered in New York, New York.

Envista NYSE:NVST

$20.00 +0.46 (+2.33%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$20.02 +0.02 (+0.12%)

As of 04:03 AM Eastern

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time